Treatment for Recurrent Vaginal Yeast Infections
Initial Diagnosis and Assessment
- RVVC is defined as four or more episodes of symptomatic vulvovaginal candidiasis (VVC) within a 12-month period, affecting approximately 5% of women 2, 3
- Vaginal cultures should be obtained to confirm the diagnosis and identify the specific Candida species, particularly to detect non-albicans species like C. glabrata 2
- Non-albicans Candida species are found in 10-20% of RVVC cases and often require different treatment approaches 2
Treatment Algorithm
- The Centers for Disease Control and Prevention recommends an initial induction therapy followed by a 6-month maintenance regimen with fluconazole 150 mg weekly, which achieves control of symptoms in >90% of patients 1
- For C. albicans RVVC, option 1 is Fluconazole 150 mg orally, with a second dose 72 hours later, followed by a third dose on day 7 1
- For non-albicans RVVC, longer duration (7-14 days) of non-fluconazole azole therapy is recommended 2
- For C. glabrata, Boric acid 600 mg in a gelatin capsule vaginally once daily for 14 days (70% eradication rate) is recommended 1, 2
Special Considerations
- Non-albicans Candida species, such as C. glabrata, respond poorly to fluconazole 1
- For C. glabrata infections, first-line treatment is Boric acid 600 mg in a gelatin capsule vaginally daily for 14 days 1, 2
- Alternative treatment for C. glabrata is topical 4% flucytosine (may require specialist referral) 2
Common Pitfalls to Avoid
- Failure to obtain cultures before initiating treatment for RVVC may miss non-albicans species 2
- Inadequate induction therapy before starting maintenance regimen can lead to persistent infection 2
- Discontinuing maintenance therapy too early (should be continued for 6 months) can lead to recurrence 1, 2
- Not monitoring for potential drug interactions with oral azoles can lead to adverse effects 2
- Self-medication with over-the-counter preparations without proper diagnosis can delay identification of other causes of vulvovaginitis 4